⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11379602 | 1.00 | — | — | |
| SCHEMBL13350944 | 0.90 | — | — | |
| SCHEMBL13485246 | 0.87 | FUCA1 (0.55) | — | |
| SCHEMBL13508249 | 0.87 | FUCA1 (0.55) | — | |
| SCHEMBL26568269 | 0.87 | FUCA1 (0.55) | — | |
| SCHEMBL13485280 | 0.87 | FUCA1 (0.55) | — | |
| SCHEMBL6932575 | 0.84 | FUCA1 (0.40) | — | |
| SCHEMBL23451903 | 0.80 | — | — | |
| SCHEMBL5868291 | 0.80 | — | — | |
| SCHEMBL23451881 | 0.78 | FUCA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | claimed |
| JP-2011525171-A | — | — | 2011-09-15 | — | — | JP | claimed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | claimed |
| EP-2265275-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BioCryst Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2010036407-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | claimed |
| EP-2114980-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | Biocryst Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| CN-101166750-A | Furanopyrimidine compounds and thienopyrimidine compounds for therapy | BIOCRYST PHARM INC (US) | 2008-04-23 | — | — | CN | claimed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2025022124-A2 | METHODS FOR DEPOLYMERISING AND REPOLYMERISING | Epoch Biodesign Ltd (GB) | 2025-01-30 | — | — | WO | disclosed |
| EP-3720835-B1 | METHOD FOR PREPARING ETHERS OF CYCLOALIPHATIC OR ARALIPHATIC DIOLS | BASF SE (DE) | 2022-07-13 | — | — | EP | disclosed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-4282388-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-04 | — | — | US | disclosed |
| EP-0002214-A1 | Benzyl ethers of cyclic 1,2-diols, methods for their preparation and their use as herbicides | BAYER AG (DE) | 1979-06-13 | — | — | EP | disclosed |